AcelRx Q2 net loss $4.4M; raises $10M in private placement; Niyad EUA pending

TALPHERA, INC.

2023-Q2 EPS reported -$1.15 revenue$253,000

Net loss attributable to common shareholders $4.4M ($0.40/share) vs net income $63.2M in Q2 2022.
Cash and cash equivalents $7.4M at June 30; proforma $17.4M after July private placement.
Closed $10M private placement led by Nantahala Capital, with potential $16.3M from warrants tied to milestones.
EUA for Niyad (nafamostat mesylate) submitted to FDA in April; responses awaited. Registrational study to start Q4 2023.
DSUVIA divested to Alora in April; AcelRx receives 15% royalty on commercial sales, 75% on DoD sales, up to $116.5M milestones.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TALPHERA, INC. reported the three months ended June 30, 2023 results: revenue $0.3 million, net income $4.4 million, EPS $0.40 per basic and diluted share. Guidance reaffirmed.

Period: the three months ended June 30, 2023
Revenue: $0.3 million
Net income: $4.4 million
EPS: $0.40 per basic and diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Information ● The cash and cash equivalents balance was $7.4 million as of June 30, 2023. The senior debt with Oxford was fully repaid in the second quarter. ● Revenues of $0.3 million for the second quarter primarily represents the royalty revenue earned on the sales of DSUVIA by Alora, principally driven by sales to the Department of Defense. Revenues in the

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-023035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.